Boteng Co., Ltd. (300363.SZ) subsidiary has obtained a drug production license.

Zhitong Finance APP News, Boteng Co., Ltd. (300363.SZ) announced that its secondary holding subsidiary, Suzhou Boteng Biopharmaceutical Co., Ltd. (referred to as "Suzhou Boteng"), recently successfully obtained the "Drug Production License" issued by the Jiangsu Provincial Drug Administration, valid until July 26, 2031. This is the first time Suzhou Boteng has obtained the "Drug Production License," marking that Suzhou Boteng is now qualified to undertake the commercialized contract manufacturing of cell and gene therapy products. This qualification provides assurance for Suzhou Boteng's future commercial contract manufacturing of cell and gene therapy CDMO and is conducive to promoting the company's cell and gene therapy CDMO business development.